Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan , Saskatoon, Saskatchewan , Canada .
J Enzyme Inhib Med Chem. 2015 Apr;30(2):259-63. doi: 10.3109/14756366.2014.913036. Epub 2014 Jun 18.
In a quest for developing novel anti-tubercular agents, a series of 3-benzylidene-4-chromanones 1a-l were evaluated for growth inhibition of Mycobacterium tuberculosis H37Rv. Three promising compounds 1d, g, j emerged as the lead compounds with the IC50 and IC90 values of less than 1 µg/mL. Evaluation of the potent compounds 1d, g, j and k against Vero monkey kidney cells revealed that these compounds are far more toxic to M. tuberculosis than to Vero cells. Structure-activity relationships demonstrated that 3-benzylidene-4-chromanones are more potent against M. tuberculosis than the related 2-benzylidene cycloalkanones and the meta substituted chromanone derivatives are more active than their ortho- and para-counterparts. Some guidelines for amplifying the project are presented.
在开发新型抗结核药物的过程中,对一系列 3-亚苄基-4-色满酮 1a-l 进行了评估,以抑制结核分枝杆菌 H37Rv 的生长。有三个有前途的化合物 1d、g、j 脱颖而出,成为具有低于 1µg/mL 的 IC50 和 IC90 值的先导化合物。对 Vero 猴肾细胞的有效化合物 1d、g、j 和 k 的评估表明,这些化合物对结核分枝杆菌的毒性远高于 Vero 细胞。构效关系表明,3-亚苄基-4-色满酮对结核分枝杆菌的活性高于相关的 2-亚苄基环烷酮,间位取代的色满酮衍生物比其邻位和对位类似物更具活性。提出了一些扩大项目的指导方针。